UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

 

July 15, 2014

 

Commission File #: 000-53723

 

TAURIGA SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Florida

(State or other jurisdiction of incorporation)

 

65-1102237

(IRS Employer Identification Number)

 

39 Old Ridgebury Road

Danbury, Connecticut 06180

(Address of principal US executive offices)

 

Tel: (917) 796-9926

(Registrant’s telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

[  ]    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ]    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

 

[  ]    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

 

[  ]    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

 

 

 
 

 

Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

 

The information in Item 2.01 is incorporated herein by reference in its entirety.

 

ITEM 2.01 COMPLETION OF ACQUISITION

 

On July 15, 2014 (the “Closing Date”), Tauriga Sciences, Inc., a Florida corporation, (the “Company”) completed its acquisition of Honeywood LLC, a California limited liability company (“Honeywood”), pursuant to the terms of an Agreement and Plan of Merger, as amended by Amendment No.1 to the Agreement and Plan of Merger, dated July 15, 2014 (collectively, the “Merger Agreement”) by and among the Company, Doc Greene’s Acquisition Sub, LLC, a limited liability company (“Honeywood Acquiror”), Honeywood, Elie Green, Daniel Kosmal and Ramona Rubin (collectively, the “Sellers”).

 

Pursuant to the terms of the Merger Agreement, on the Closing Date, Honeywood Acquiror merged with and into Honeywood, with Honeywood being the surviving entity and becoming a wholly owned subsidiary of the Company (the “Merger”). A description of the exchange of membership interests was contained in the Company’s Current Report on Form 8-K, dated March 14, 2014 and is incorporated by reference hereto.

 

In addition, the parties to the Merger Agreement, dated March 10, 2014, agreed to amend certain terms of the merger simultaneously with the closing of the Merger. The material changes set forth in the Amendment No. 1 to the Merger Agreement included: (i) the reduction of the purchase price from 32% of the Company’s restricted shares of common stock to approximately to 15.457% of the Company’s restricted shares of common stock (or 109,414,235 shares of restricted common stock) paid on a pro rata basis to the Sellers at the Closing , (ii) the addition of the payment of 18,000,000 shares of the Company’s restricted shares of common stock paid at closing to Royal Oak Consulting, LLC in connection with the satisfaction of any fees owed to it by Honeywood prior to Closing, (iii) the addition of a covenant that the Sellers will have the opportunity to collectively earn up to an additional aggregate equal to 10% of the Company’s restricted shares common stock outstanding (utilizing the same initial Closing Date) upon achieving the following gross revenue based milestones: upon the generation and receipt of $2,000,000 of gross revenues derived strictly from the sale and licensing of Honeywood’s products, the Sellers shall each be issued either restricted stock or stock options equal to 1.6666% shares of common stock of the Company upon the generation and receipt of an additional $2,000,000 ($4,000,000 total gross revenues by Honeywood), the Sellers shall each be issued an additional 1.6666% restricted shares of common stock of the Company (each such additional issuance to be set off the outstanding shares immediately prior to the Closing Date), and (iv) address a plan for management of Honeywood following the merger.

 

In connection with the closing of the merger, each of the Sellers entered a Release and Covenant Not to Sue in favor of the Company, and a Standstill Agreement with the Company, agreeing to restrictions on acquisition of additional Company capital stock and transactions involving Company.

 

The foregoing descriptions of the Merger Agreement, Amendment No. 1 to the Agreement and Plan of Merger, the Release and Covenant Not to Sue, the Standstill Agreement (collectively, the “Agreements”) do not purport to be complete and are qualified in their entirety by reference to the full text of the Agreements. Further, the foregoing description of the Company’s acquisition of Honeywood is qualified in its entirety by reference to the Agreements. The Merger Agreement was included as Exhibit 2.1 to the Company’s Current Report on Form 8-K as filed with the Securities and Exchange Commission (the “Commission”) on March 14, 2014 and is incorporated herein by reference. Each of Amendment No. 1 to the Agreement and Plan of Merger, the Release and Covenant Not to Sue and Standstill Agreement are attached as Exhibits 2.1, 10.1 and 10.2, respectively, to this current report on form 8-K, and are incorporated herein by reference hereto.

 

This Current Report on Form 8-K is neither an offer to sell nor the solicitation of an offer to buy any securities. The securities described herein have not been registered under the Securities Act and may not be offered or sold in the United States of America absent registration or an exemption from registration under the Securities Act.

 

 
 

 

Item 3.02 Unregistered Sales of Equity Securities

 

The information in Item 2.01 is incorporated herein by reference in its entirety.

 

The issuance and sale of the shares of the Company’s common stock issued in connection with the Merger are exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof.

 

Item 8.01 Other Events.

 

On July 14, 2014, the Company issued a press release announcing the Merger. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference in its entirety.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(a) Financial statements of business acquired.

 

( b) Pro forma financial information.

 

Any financial statements and pro forma financial information required by this Item will be filed by amendment to this Current Report on Form 8-K within 71 calendar days from the date that this Current Report on Form 8-K must be filed with the Securities and Exchange Commission.

 

(d) Exhibits

 

The following exhibits are furnished or filed as part of this Current Report on Form 8-K:

 

2.1   Amendment No. 1 to the Agreement and Plan of Merger, dated July 15, 2014
   
10.1   Release and Covenant Not to Sue, dated July 15, 2014
     
10.2   Standstill Agreement, dated July 15, 2014
     
99.1   Press release, dated July 14, 2014

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TAURIGA SCIENCES, INC.
       
Date: July 21, 2014 By: /s/ Stella M. Sung  
    Stella M. Sung  
    Chief Executive Officer  

 

 
 

 

 

Amendment no. 1 to the AGREEMENT AND PLAN OF MERGER

 

THIS AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER (this “ Amendment ”) is entered into as of July 15, 2014, by and among Tauriga Sciences, Inc., a Florida corporation (“ Tauriga ”), Doc Greene’s Acquisition Sub, LLC, a California limited liability company and wholly-owned subsidiary of Tauriga (“ Acquisition Sub ” and together with Tauriga, the “ Purchasers ”), Honeywood LLC, a California limited liability company (“ Honeywood ”) and the current limited liability company members of Honeywood LLC (which are Elie Green, Daniel Kosmal and Ramona Rubin) (“ Members ”, and together with Honeywood, collectively referred to as “ Sellers ”, or each a “ Seller ”). Tauriga, Acquisition Sub, Honeywood, and, upon their execution hereof, the Members party hereto are each referred to herein as a “ Party ” or collectively as the “ Parties ”.

 

RECITALS

 

WHEREAS , the Parties entered into that certain Agreement and Plan of Merger dated as of March 10, 2014 (the “ Merger Agreement ”);

 

WHEREAS , the Parties desire to amend the Merger Agreement as set forth in this Amendment.

 

NOW, THEREFORE , in consideration of the premises and the mutual promises herein made, and in consideration of the representations, warranties, and covenants herein contained, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound hereby, the Parties agree as follows.

 

1. Incorporation of Preliminary Statements; Defined Terms . The recitals set forth above are hereby incorporated by reference into this Amendment. Capitalized terms used, and not otherwise defined herein, shall have the meanings given to such terms in the Merger Agreement.

 

2. Amendment to the Merger Agreement . The Parties hereby amend the Merger Agreement as set forth below:

 

(a) Recitals; Definition of Product . The first recital of the Merger Agreement is deleted and replaced in its entirety with the following:

 

WHEREAS , Honeywood is engaged in the business of developing and/or marketing a line of beauty and topical wellness products harnessing the power of cannabis including, but not limited to, topical lotions, balms, gels, sprays, roll-ons, patches, shampoos, capsules, pills, oils, waxes, aerosols, cartridges, pens or teas (the “ Product ”).”

 

Additionally, the lower case word “product” in the following Sections of the Merger Agreement shall be replaced with the initial capitalized word “Product:” Sections 1.2(a) , 2.10(a) , 2.14(f) , 2.24 , 4.2(p) , 4.2(t) and 5.18 .

 

1
 

 

(b) Closing Date . Section 1.1(b) of the Merger Agreement is deleted in its entirety and replaced with the following:

 

“(b) The Closing . The closing of the transactions contemplated by this Agreement (the “ Closing ”) shall take place at the offices of Nixon Peabody LLP, 437 Madison Avenue, New York, New York 10022, commencing at 11:00 a.m. local time on the earlier to occur of (a) the business day following the date on which all the conditions set forth in Sections 4.1 and 4.2 have been satisfied or waived (other than conditions with respect to actions the respective Parties will take at the Closing itself), or (b) within one-hundred twenty (120) days immediately following the execution of this Agreement or (c) such other date as the parties may mutually determine in writing (the “ Closing Date ”).”

 

(c) Conversion Ratio; Restrictions on Transfer of Merger Shares . Section 1.2(c) of the Merger Agreement is deleted in its entirety and replaced with the following:

 

(c) Issuance of Tauriga Common Stock . At the Closing, the sole and single class of issued and outstanding membership interests of Honeywood (collectively, the “ Honeywood Interests ”) shall be converted into the right to receive up to such number of restricted shares of Tauriga’s common stock, $.00001 par value per share determined as follows: in exchange for 100% of the membership interests in Honeywood, Tauriga is offering restricted shares of its common stock equal to 109,414,235 of its outstanding common stock (determined as of the date immediately preceding the Closing Date), which shall be on a non-diluted basis (the “ Merger Shares ”) and issued at Closing (so that Elie Green, Daniel Kosmal and Ramona Rubin (the “ Honeywood Principals ”) will collectively receive shares of Tauriga restricted common stock equal to an aggregate of 15.457% of the outstanding shares of Tauriga (on a non-diluted basis) at Closing, determined as set forth above; or if the Honeywood Principals do not hold equal percentages in Honeywood prior to the Closing, then the Merger Shares shall be allocated among the holders of Honeywood Interests in accordance with his or its respective proportional holdings of Honeywood Interests as of the Closing; provided, however , for the avoidance of doubt, no Person will be entitled to Merger Shares unless such Person has been admitted as a Member of Honeywood prior to the Effective Time and is a Party to this Agreement. In addition, and notwithstanding the foregoing, Tauriga shall issue 18,000,000 (restricted) shares of its common stock to Royal Oak Consulting, LLC in connection with satisfaction of any fees owed by Honeywood to Royal Oak Consulting, LLC pursuant to that certain Consulting Agreement by and between Honeywood and Royal Oak Consulting, LLC dated October 28, 2013. No fractional shares of Tauriga Common Stock will be issued in the Merger upon the surrender for exchange of the Honeywood Interests, and any such fractional share interests will not entitle the owner thereof to any rights of a stockholder of Tauriga. Each Member who is entitled to one-half or more of a Merger Share will receive a full Merger Share, and any fractional interests of less than one-half of a Merger Share will be canceled. Each of the Members agrees that no Merger Shares or shares of Option Stock may be gifted, assigned, transferred or sold by the Sellers, except in compliance with applicable securities laws, rules and regulations.”

 

2
 

 

Additionally, Section 1.2(d) of the Merger Agreement is amended by deleting the words: “in accordance with the Conversion Ratio” in the first sentence of such Section; and Section 1.5(e) of the Merger Agreement is deleted in its entirety and replaced with the following: “(e) Reserved.”

 

(d) Milestone Common Stock Issuances . Section 1.3 of the Merger Agreement is deleted in its entirety and replaced with the following:

 

“1.3 Additional Issuances . Tauriga shall reserve such number of shares of its unregistered shares of common stock equal to an aggregate of 10.0% of its outstanding common stock (the “ Option Stock ”) (such share number to be determined as of the date immediately preceding the Closing Date), which will be issuable on the achievement of gross revenue milestones as follows:

 

(a) From and after the Closing Date, upon the generation and receipt by the Surviving Entity of $2.0 million of gross revenues (as demonstrated by sales receipts and the deposit of such revenues into the bank account of the Surviving Entity, as shall have been established by Tauriga pursuant to the terms hereof) derived strictly from the sale of DocGreen’s and Honeywood’s products approved by the Board of Managers, whether sold directly, licensed or otherwise (the “ First Milestone ”), Elie Green, Daniel Kosmal and Ramona Rubin shall each be issued an additional 1.6666% of the Option Stock within five (5) business days upon verification by Tauriga of such books, receipts and bank records; provided, however , that such Person is employed with Honeywood or another Affiliate of Tauriga at the time of such Option Stock payment; and

 

(b) Following achievement of the First Milestone, upon the generation and receipt by the Surviving Entity of an additional $2.0 million of gross revenues (the “ Second Milestone ”) (as demonstrated by sales receipts and the deposit of such revenues into the bank account of the Surviving Entity, as shall have been established by Tauriga CEO or accountant pursuant to the terms hereof) derived strictly from the sale of Doc Green’s and Honeywood’s products approved by the Board of Managers, whether sold directly, licensed or otherwise, Elie Green, Daniel Kosmal and Ramona Rubin shall each be issued an additional 1.6666% of the Option Stock within five (5) business days upon verification by Tauriga’s CEO or accountant of such books, receipts and bank records; provided, however , that such Person is employed with Honeywood or another Affiliate of Tauriga at the time of such Option Stock payment.

 

3
 

 

(c) In connection with the revenue based milestone earn-out set forth in paragraphs (a) and (b) of this Section 1.3, following a further tax analysis by tax a professional(s) and further discussion with Tauriga (to allow for sufficient time to implement such plan among other related items, such as vesting, and the like), in the event that the Sellers have determined that the tax liability to them would be lessened by opting for receipt of vesting stock options (pursuant to a plan to be implemented by Tauriga), rather than receiving restricted stock (i.e., not through a qualified stock option plan), then Tauriga agrees to issue such stock options rather than restricted stock directly to the Sellers, as set forth above.”

 

(e) Cross-References . Section 1.6 of the Merger Agreement is amended by inserting in correct alphabetical order, the following:

 

  Advances Section 5.10
     
  Escrow Account Section 5.10
     
  “First Milestone” Section 1.3(a)
     
  “Honeywood Director” Section 4.1(k)
     
  Option Stock Section 1.3
     
  “Restricted Employees” Section 5.20
     
  “Restricted Period” Section 5.20
     
  Second Milestone Section 1.3(b)
     
  “Securities Purchase Agreement” Section 5.10
     
  WC Financing Section 5.10

 

4
 

 

(f) Finalization of Representations and Warranties . The lead-in paragraphs to Article II of the Merger Agreement are hereby deleted in their entirety and replaced with the following:

 

Subject to the disclosures set forth in the disclosure letter of Honeywood and the Sellers as provided to the Purchasers on the date hereof (the “ Disclosure Schedules ”), Honeywood represents and warrants to Tauriga and Acquisition Sub that each of the following statements is true and correct as of as of the date hereof and shall be true and correct as of the Closing Date (except for representations and warranties which address matters only as to a specified date, which representations and warranties shall be true and correct with respect to such specified date), and each other Seller severally represents and warrants to Tauriga and Acquisition Sub that each of the statements set forth in Sections 2.1, 2.2, 2.3, 2.4(a) and 2.19 of this Agreement shall be true and correct as of the date hereof (the “ Finalization Date ”) (except for representations and warranties which address matters only as to a specified date, which representations and warranties shall be true and correct with respect to such specified date).

 

If in any supplement or amendment of the Disclosure Schedules is delivered by the Sellers or Honeywood after the Finalization Date, or Honeywood or the Sellers disclose an event, change or circumstance which constitutes a Material Adverse Effect, the Purchasers shall have the right to terminate this Agreement as provided in Article VIII and such termination shall be the Purchasers’ sole and exclusive remedy relating to any matters set forth in such supplement or amendment; provided however, that if Purchasers do not terminate this Agreement within the timeframe set forth in such Section, Purchasers will be deemed to have accepted such supplement or amendment to the Disclosure Schedules, and the event, change or circumstance so disclosed in such supplement shall not be deemed to constitute a Material Adverse Effect or serve as the basis for termination pursuant to Article VIII or otherwise.”

 

(g) Intellectual Property Representations and Warranties . Section 2.10 of the Merger Agreement is amended by adding immediately before the words ‘(“ Honeywood IP ”)’, the following:

 

“, including, for the avoidance of doubt, any of the foregoing (i) through (iii) shall include ‘DocGreen’s’ Intellectual Property and their respective variations”

 

Section 2.10 of the Merger Agreement shall be further amended by adding the following subsection (i) after the subsection numbered (h) thereof:

 

“(i) Honeywood is the sole and exclusive owner of all right, title and interest in Doc Green’s, the Intellectual Property and ‘DocGreen’s’ marks and their variations, including any Products utilizing such Intellectual Property.”

 

(h) Investment Representations and Warranties . Section 2.19 is amended by replacing the words “Merger Shares”, in each place that such words appear in such Sections, with the words “Merger Shares and shares of Option Stock, if any” or “Merger Shares or shares of Option Stock, if any,” as the context requires.

 

5
 

 

(i) WC Financing . Section 4.1(f) of the Merger Agreement is deleted in its entirety and replaced with the following:

 

“(f) Financing . Tauriga has secured Magna’s commitment of $1M pursuant to the terms of a securities purchase agreement between Tauriga and Magna, dated March 7, 2014 (the “ Magna SPA ”); however, based on Tauriga’s stock price at or near the closing of the Magna SPA and pursuant to the terms thereunder, such commitment may be reduced to as low as $525K (solely as a function of the per share stock price of Tauriga). Such monies will be funded to the escrow account of the Quick Law Firm (the “ Escrow Account ”) and released to Tauriga pursuant to the terms of the escrow and purchase agreement between Tauriga and Magna, and then deposited in the Bank Account of the Surviving Entity within one business day of establishing such Bank Account in accordance with the terms hereof. Should Magna’s ultimate commitment under the Magna SPA total less than $1MM (due to possible stock price fluctuations of Tauriga, as noted above), Tauriga shall remain obligated to have committed an aggregate total of $825,000 for the working capital of the Surviving Entity (the “ WC Financing ”, which is calculated as a total of $1MM, less the advance of $175K which was previously made by Tauriga to Honeywood following execution of the Merger Agreement on March 10, 2014 pursuant to Section 1.2(a) of the Merger Agreement). It is agreed and acknowledged that the WC Financing shall be exclusively used for the operating capital of the Surviving Entity. Use and distribution of such proceeds will be utilized in consultation with and approval by the Surviving Entity’s Board of Managers. Notwithstanding the provisions of Section 5.10 , it is acknowledged and agreed that the Members of Honeywood have received an additional twelve thousand and five hundred dollars USD ($12,500.00) from Tauriga to pay Buhalter Nemer P.C. for its legal fees incurred solely in connection with this Merger, and will receive an additional $7,500.00 from Tauriga.”

 

6
 

 

Section 5.10 of the Merger Agreement is additionally amended by deleting it in its entirety and replacing it with the following:

 

“5.10 Financing . Tauriga has secured Magna’s commitment of $1M pursuant to the terms of a securities purchase agreement between Tauriga and Magna, dated March 7, 2014 (the “ Magna SPA ”); however, based on Tauriga’s stock price at or near the closing of the Magna SPA and pursuant to the terms thereunder, such commitment may be reduced to as low as $525K (solely as a function of the per share stock price of Tauriga). Such monies will be funded to the escrow account of the Quick Law Firm (the “ Escrow Account ”) and released to Tauriga pursuant to the terms of the escrow and purchase agreement between Tauriga and Magna, and then deposited in the Bank Account of the Surviving Entity within one business day of establishing such Bank Account in accordance with the terms hereof. Should Magna’s ultimate commitment under the Magna SPA total less than $1MM (due to possible stock price fluctuations of Tauriga, as noted above), Tauriga shall remain obligated to have committed an aggregate total of $825,000 for the working capital of the Surviving Entity within fifteen (15) business days of the Closing Date (the “ WC Financing ”, which is calculated as a total of $1MM, less the advance of $175K which was previously made by Tauriga to Honeywood following execution of the Merger Agreement on March 10, 2014 pursuant to Section 1.2(a) of the Merger Agreement). It is agreed and acknowledged that the WC Financing shall be exclusively used for the operating capital of the Surviving Entity. Use and distribution of such proceeds will be utilized in consultation with and approval by the Surviving Entity’s Board of Managers. Notwithstanding the provisions of , it is acknowledged and agreed that the Members of Honeywood have received an additional twelve thousand and five hundred dollars USD ($12,500.00) from Tauriga to pay Buchalter Nemer P.C. for its legal fees incurred solely in connection with this Merger, and will receive an additional seven thousand and five hundred dollars ($7,500.00) from Tauriga”

 

(j) Form S-1 Effectiveness . Section 4.2(i) of the Merger Agreement is deleted in its entirety and replaced with the words “(i) Reserved.”

 

(k) Employment Agreements . Section 4.2(r) of the Merger Agreement is amended by adding after the words “California laws, the words: “, and in forms acceptable to Tauriga and to the Sellers.”

 

(l) ATM Lock-up . Section 5.11 of the Merger Agreement is deleted in its entirety and replaced with the following:

 

“5.11 ATM Lock-up . Immediately following the Closing Date, Tauriga’s EEP securities drawn under its common stock purchase agreement (“ ATM ”) entered into between Tauriga and Hanover Holdings I, LLC, a New York limited liability company on June 13, 2013, shall be unlocked and will be immediately available for use by Tauriga in its sole discretion pursuant to the terms thereunder; provided, however , that Tauriga covenants to reserve an aggregate equal to 50% of the existing ATM shares (determined as of the Closing Date) to be used solely for the necessary expenses and operations of the Surviving Entity’s growth, business operations, expansion or other working capital needs from the ATM between the Closing Date and July 30, 2016, if necessary. Any such use of ATM funds shall be made upon the request of the Board of Managers and ultimately with the approval of Tauriga’s Board of Directors. The Board of Managers shall convene and discuss whether the ATM or such other funding source shall be used, if necessary, for the Surviving Entity at such time. ”

 

7
 

 

(m) Taxes; 10b5-1 Plan . Section 5.13(f) of the Merger Agreement is deleted in its entirety and replaced with the following:

 

Within thirty (30) days following the Closing Date, following consultation with tax professionals, to the extent necessary to satisfy the Members’ respective tax consequences arising solely out of the receipt of the Merger Shares, Tauriga agrees to use its best efforts to assist such Member in setting up and entering into a 10b5-1 Plan for the purpose of selling such number of Merger Shares sufficient to satisfy such Seller’s estimated and unpaid tax liability generated by the receipt of the Merger Shares or other merger consideration, but only up to such number of Merger Shares as then necessary to satisfy such tax consequence, and in compliance the Securities Act, the Exchange Act, and the respective rules and regulations thereunder.”

 

(n) Bank Account . Section 5.16 of the Merger Agreement is deleted in its entirety and replaced with the following:

 

“Tauriga shall have, within three (3) business days following the Closing Date, established a commercial bank account solely for the Surviving Entity (the “Bank Account”) with a bank of its choice, which account shall be held by Tauriga (through its CEO), and utilized (including any WC Financing funds and any other funds thereafter derived from the Surviving Entity’s business or elsewhere) solely for the Surviving Entity’s working capital, expansion and/or maintenance of its business operations, with the goal of a substantial increase in its revenues and growth of the Surviving Entity’s business. None of Elie Green, Daniel Kosmal or Ramona Rubin shall be signatories to the Bank Account of the Surviving Entity, nor shall Elie Green, Ramona Rubin or Daniel Kosmal establish or have established on their behalf, any other bank account for use by, for or in conjunction with the Surviving Entity’s business or operations.

 

In addition, an expense account shall be established by Tauriga for Elie Green, Daniel Kosmal or Ramona Rubin, which shall be linked to the Bank Account, with an aggregate $10,000 limit for the sole use of operating expenses related to the Surviving Entity for projects previously approved by the Board of Managers or for such pre-approved activities in the Honeywood Operational Plan within such limit. Any expense above $10,000, if not previously agreed to by the Board of Managers, shall be discussed for approval by the Board of Managers in the ordinary course. Notwithstanding the foregoing, the expenses as identified on Exhibit 5.16(n) have been pre-approved and shall not be subject to the aforementioned limitations.”

 

8
 

 

(o) Board of Managers of Surviving Entity . Section 5.17 of the Merger Agreement is deleted in its entirety and replaced with the following:

 

“5.17 Surviving Entity Board of Managers . On or before the Closing Date, Tauriga and the Sellers will form a Board of Managers of the Surviving Entity (the “ Board of Managers ”), which will oversee and approve the day to day operations of the Surviving Entity following the closing of the Merger. The Board of Managers will consist of the following individuals with the following voting rights:

 

Dr. Stella Sung or the CEO of Tauriga from time to time – 1.0 vote

 

Dr. Larry May – 1.0 vote

 

Elie Green – 2/3 of one vote

 

Daniel Kosmal – 2/3 of one vote

 

Ramona Rubin – 2/3 of one vote.

 

Elie Green, Daniel Kosmal and Ramona Rubin collectively shall hold a total of two (2) votes on the Board of Managers, and they may but are not required to vote as a block on any decision of the Board of Managers.

 

In the event that Tauriga effects a sale of all or substantially all of its assets, or a tender offer or exchange offer (which is not in the form of a hostile takeover) is completed pursuant to which holders of Tauriga’s common stock owning more than 50% of the outstanding shares of common stock (not including any shares of common stock held by the Person or Persons making, or affiliated with the Persons making the tender or exchange offer) tender or exchange their shares for other securities, cash or property, Tauriga agrees to use its best efforts to maintain the existing composition of the Board of Managers; however , it is agreed and acknowledged that the Tauriga representatives may be replaced by such buyer following the closing of such transaction.

 

The governance and voting of the Board of Managers of the Surviving Entity shall be administered in connection with its Limited Liability Company Operating Agreement attached hereto as Exhibit A .

 

(p) Form S-1 Effectiveness . Tauriga shall use its reasonable best efforts to, within thirty (30) days following the latter of the (i) Closing Date, and (ii) filing of the Company’s annual report for the year ended March 30, 2014, file a Form S-1 Registration Statement pursuant to the terms of that Magna Spa, as amended, to register for resale the underlying securities issuable pursuant to a Warrant being sold to such investor in exchange for the WC Financing.

 

9
 

 

(q) Additional Covenants of Sellers . A new Section 5.20 is inserted immediately after Section 5.19 of the Merger Agreement as follows:

 

“(a) Each Seller covenants and agrees that, from the Closing Date through the three (3) year anniversary of the Closing Date (the “ Restricted Period ”), it will not for its own account, jointly with another, or for or on behalf of any Person, directly or indirectly:

 

(i) engage or participate, or assist any other Person to engage or participate, whether as an owner, investor, partner, member, security holder, independent contractor, licensor, licensee, officer, member of the board of directors or managers, employee, supervisor, consultant, agent, guarantor, lender, advisor or otherwise (without limitation by the specific enumeration of the foregoing) in or with any business that develops and/or markets cannabis products similar to the Product; provided, however, that nothing in this Section 5.20(a)(i) will prohibit any such Person from owning, in the aggregate, less than two percent (2%) of any class of securities of any public company;

 

(ii) recruit, induce, or solicit, or in any manner attempt to recruit, induce, or solicit, any Person that is at such time or during the previous one (1) year period was an employee, independent contractor or consultant of Tauriga, Honeywood or Surviving Entity (“ Restricted Employees ”); provided, however , that no Seller shall be restricted from placing general solicitation notices of available positions within it and its Affiliates in internal and external print and electronic media that are not specifically directed at any Restricted Employees;

 

(iii) solicit any Person that is at such time a customer, supplier or business associate of Tauriga, Honeywood or Surviving Entity for the purpose of offering or providing services or products which are competitive with the Product or any products or services provided by Tauriga, Honeywood or Surviving Entity; or

 

(iv) cause or seek to cause to be terminated or adversely affected, or otherwise interfere with, any Contract or other business relationship of any kind to which the Tauriga, Honeywood or Surviving Entity is a party or from which any of them benefit, including relationships with such Person’s suppliers, customers and other professional and business contacts.

 

10
 

 

(b) Each of the Parties agrees that a violation of the terms, provisions, obligations, duties and conditions described in this Section 5.20 will cause irreparable damage to the other Parties for which money damages or other legal remedies would not be an adequate remedy. Accordingly, each Seller acknowledges and hereby agrees that in the event of any breach or threatened breach by it of any of its covenants or obligations set forth in this Section 5.20 , the other Parties shall be entitled, in any court in the United States or otherwise having jurisdiction, to an injunction or injunctions, without the posting of any bond or establishing of damages, to prevent or restrain breaches or threatened breaches of this Section 5.20 , and to specifically enforce the terms and provisions of this Section 5.11 to prevent breaches or threatened breaches of, or to enforce compliance with, the covenants and obligations of this Section 5.20 . Each Seller hereby agrees to not challenge the enforceability of the restrictive covenants contained in this Section 5.20 or raise any objections to the availability of the equitable remedy of specific performance to prevent or restrain breaches or threatened breaches of this Section 5.20 , and to specifically enforce the terms and provisions of this Section 5.20 to prevent breaches or threatened breaches of, or to enforce compliance with, the covenants and obligations under such this Section 5.20 . Each Party further agrees that the commencement of any Proceeding pursuant to this Section 5.20 or anything set forth in this Section 5.20 will not restrict or limit the other Party’s right to pursue any other remedies under this Agreement or otherwise that may be available to the other Party thereafter. 

 

(c) If any covenant or restriction contained in this Section 5.20 , or any part thereof, is hereafter construed or found to be invalid or unenforceable in part or in whole, this shall not affect the remainder of the covenants or restrictions, which shall be given full effect, without regard to the invalid portions, and any court having jurisdiction shall enforce such invalid covenant or restriction to the maximum extent possible under applicable law, including the maximum permissible time, scope and geographic area for such covenant or restriction.”

 

3. Representations and Warranties . For the avoidance of doubt, the date hereof shall be the “Finalization Date” for all purposes of the Merger Agreement, and the representations and warranties as amended by this Amendment shall be the “Amended Representations and Warranties” for all purposes of the Merger Agreement.

 

4. Miscellaneous . Section 9.1 through 9.7 and 9.9 through 9.12 are, mutatis mutandis , incorporated herein by reference. The Merger Agreement and this Amendment contain the entire understanding of the Parties with respect to the subject matter hereof, and supersede all prior representations, agreements and understandings relating to the subject matter hereof. In the event of an inconsistency between the terms of the Merger Agreement and this Amendment with respect to the matters the subject matter hereof, this Amendment will govern.

 

[Signature page follows]

 

11
 

 

IN WITNESS WHEREOF, this Agreement has been duly executed by the Parties hereto as of the date first written above.

 

  TAURIGA SCIENCES, INC.
     
  By: /s/ Stella M. Sung
  Name: Stella M. Sung, Ph.D
  Title: Chief Executive Officer
     
  DOC GREENE’S ACQUISITION SUB, LLC
     
  By: /s/ Stella M. Sung
  Name: Stella M. Sung, Ph.D
  Title: President and CEO of Tauriga Sciences, Inc., sole member
     
  HONEYWOOD, LLC
     
  By: /s/ Daniel Kosmal
  Name: Daniel Kosmal
  Title: President
     
  HONEYWOOD’S MEMBERS
   
  /s/ Elie Green
  Elie Green
   
 

/s/ Daniel Kosmal

  Daniel Kosmal
   
 

/s/ Ramona Rubin

  Ramona Rubin

 

[Signature Page to Amendment No. 1 to Merger Agreement]

 

 
 

 

 

RELEASE AND COVENANT NOT TO SUE

 

THIS RELEASE AND COVENANT NOT TO SUE (this “ Release ”) is made as of July 15, 2014, by Honeywood, LLC, a California limited liability company and the other Members from time to time party to the Merger Agreement as defined below (each a “ Releasor ” and together the “ Releasors ”), in favor of Tauriga Sciences, Inc., a Florida corporation (“ Tauriga ”) and Doc Greene’s Acquisition Sub, LLC, a California limited liability company (“ Acquisition Sub ” and together with the Tauriga, the “ Releasees ”). The Releasors and Releasees are collectively referred to as “ Parties ” and each a “ Party ”.

 

RECITALS

 

WHEREAS , the Parties are parties to that certain Agreement and Plan of Merger, dated as of as of March 10, 2014, as amended.

 

WHEREAS , Daniel Kosmal, Ramona Rubin and Elie Green are each members and officers of Honeywood, LLC.

 

WHEREAS , pursuant to Section 4.2(h) of the Merger Agreement, the Releasors are required to enter into this Release as a condition to the consummation of the transactions set forth in the Merger Agreement.

 

WHEREAS , capitalized terms used herein without definition shall have the respective meanings set forth in the Merger Agreement.

 

NOW, THEREFORE , in consideration of the premises and mutual promises herein made, and in consideration of the representations, warranties and covenants herein contained, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound hereby, the Releasors hereby covenant and agree as follows:

 

RELEASE

 

1. General Release . Each of the Releasors, for itself and its legal representatives, members, managers, employees, successors, assigns and each and every individual, entity or other person having any right or claim through, under or by reason of its relationship with the Releasor, does hereby irrevocably and unconditionally: (A) release, remise, acquit, and forever discharge: (i) the Releasees and each of their respective managers, directors, officers, shareholders, members, employees, agents and representatives, and (ii) the respective estates, legal and personal representatives, executors, administrators, heirs, successors and assigns of the Persons referred to in the preceding clause (A)(i) (with the Persons referred to in the preceding clauses (A)(i) and (ii) being collectively included within the definition of the “ Releasees ”) of and from any and all claims, demands, actions, causes of action, suits, costs, debts, damages, losses, compensation, contracts, agreements, controversies, penalties, setoff or similar rights and other liabilities and obligations of any kind or nature whatsoever, which such Releasor has or has ever had against or with respect to any of the Releasees, other than the rights set forth in the Merger Agreement (collectively, the “ Claims ”), and (B) waive, release, settle and disclaim any rights or other interest it may have with respect to the Claims, from the beginning of time to and including the date of this Release.

 

 
 

 

2. Complete Release . Notwithstanding any other provision of this Release to the contrary, each Releasor hereby acknowledges and agrees that this Release is intended to include in its effect, without limitation, all Claims that are subject to Section 1 of this Release of any kind or nature whatsoever which have arisen, known and unknown, contingent or otherwise, including without limitation those of which the Releasor knows or does not know, should have known, had reason to know or suspects to exist in such Releasor’s favor at the time of execution hereof, and that this Release will be effective as a bar to all Claims released by this Release.

 

3. Covenant Not To Sue . Each Releasor, for itself and its legal representatives, members, managers, shareholders, directors, officers, employees, successors, assigns and each and every Person having any right or claim through, under or by reason of its relationship with such Releasor, does hereby covenant not to initiate, continue or maintain any Proceeding against any Releasee before any court, Governmental Entity or other forum by reason of any Claims released by this Release. If any court, Governmental Entity or other forum assumes jurisdiction over any Claim against any Releasee released by this Release, then such Releasor will promptly direct such court, Governmental Entity or forum to withdraw from or dismiss the matter with prejudice. If such Releasor violates this Release by initiating any Proceeding against any Releasee before any court, Governmental Entity or other forum by reason of any Claims released by this Release, then such Releasor will pay all Costs (including attorney’s fees and Costs) incurred by such Released Party in defending against such Proceeding.

 

4. Binding Effect . This Release shall be binding upon each Releasor and its respective successors, heirs, personal representatives and assigns and shall be enforceable and inure to the benefit of the Releasees and their respective successors, heirs, personal representatives, and assigns. After the date of this Release, such Releasor may discover facts different from or in addition to those now known or believed to be true regarding the subject matter of this Release, but this Release will remain in full force and effect, notwithstanding the existence of any different or additional facts.

 

5. No Rule of Construction . The Parties acknowledge that each Party has been represented by counsel and all Parties have read and negotiated the language used in this Release. The Parties agree that, because all Parties participated in negotiating and drafting this Release, no rule of construction shall apply to this Release which construes ambiguous language in favor of or against any Party by reason of that Party’s role in drafting this Release.

 

6. Governing Law . This Release shall be construed and enforced in accordance with and governed by the laws of the State of Delaware without regard to principles of conflicts of laws.

 

7. Counterparts; Signatures; Section Headings . This Release may be executed by the Parties in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute but one and the same instrument. A facsimile signature shall bind the signatory in the same way that an original signature would bind the signatory. The headings of each section, subsection or other subdivision of this Agreement are for reference only and shall not limit or control the meaning thereof.

 

 
 

 

8. Submission to Jurisdiction . All actions or proceedings arising in connection with this Release shall be tried and litigated exclusively in Chancery Court of the State of Delaware. The aforementioned choice of venue is intended by the Parties to be mandatory and not permissive in nature, thereby precluding the possibility of litigation between the Parties with respect to or arising out of this Release. Each Party hereby waives: (i) any right it may have to assert the doctrine of forum non conveniens or similar doctrine or to object to venue with respect to any proceeding brought in accordance with this paragraph, and (ii) the right each may have to a trial by jury. Each Party stipulates that the Chancery Court of the State of Delaware shall have in personam jurisdiction over each of them for the purpose of litigating any such dispute, controversy or proceeding. Each Party hereby authorizes and accepts service of process sufficient for personal jurisdiction in any action against it as contemplated by this paragraph by registered or certified mail, return receipt requested, postage prepaid, to its address for the giving of notices as set forth in this Release. Nothing herein shall affect the right of any party to serve process in any other manner permitted by law.

 

9. Notices . All notices, consents, directions, approvals, instructions, requests and other communications required or permitted by the terms of this Release shall be in writing, and shall be sent to the applicable Party at the following addresses or facsimile numbers, as applicable:

 

If to any Releasee:

 

c/o Tauriga Sciences, Inc.

39 Old Ridgebury Road, Suite C4

Danbury, CT 06180

Attn: Seth M. Shaw

Telephone: (514) 840-3697

Fax: (514) 221-3336

 

With a copy to:

 

Nixon Peabody LLP

437 Madison Avenue

New York, New York 10014

Attn: Theodore J. Ghorra, Esq.

Telephone: (212) 940-3072

Fax: (855) 856-7298

 

If to any Releasor:

 

c/o Honeywood, LLC

1999 Harrison Street

Suite 1800

Oakland CA 94707

Attn: Daniel Kosmal

 

 
 

 

With a copy to:

 

Buchalter Nemer, PC

1000 Wilshire Boulevard

Suite 1500

Los Angeles, CA 90017

Attn: Jeremy Weitz, Esq. and Tanya Viner, Esq.

Tel: (213) 891-0700

Fax: (213) 630-5793

 

or to such other address or facsimile number as any Party may have furnished to each other Party in writing in accordance herewith. All notices, consents, directions, approvals, instructions, requests and other communications hereunder shall be sent and effective as follows: (i) on the business day delivered, when delivered personally, (ii) five (5) business days after mailing if mailed by registered or certified mail, return receipt requested (postage prepaid), (iii) on the next business day if sent by a nationally recognized overnight express courier service with all costs prepaid and provided evidence of delivery is available, or (iv) on the business day of a facsimile transmission if received on a business day before 5:00 p.m., local time, or on the next business day if received after that time, in each case provided that an automatic machine confirmation indicating the time of receipt is generated.

 

10. Severability . Any provision of this Release that is invalid, illegal or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability, without affecting in any way the remaining provisions hereof in such jurisdiction or rendering that or any other provision of this Release invalid, illegal or unenforceable in any other jurisdiction.

 

[Remainder of page intentionally left blank]

 

 
 

 

IN WITNESS WHEREOF, the undersigned Releasor has executed this Release as of the date first above written.

 

RELEASOR: HONEYWOOD, LLC
     
  By:

/s/ Daniel Kosmal

  Name: Daniel Kosmal  
  Title: President
     
  /s/ Daniel Kosmal
 

Daniel Kosmal

 
     
  /s/ Elie Green
  Elie Green  
     
  /s/ Ramona Rubin
 

Ramona Rubin

 

 

[Signature page to Release and Covenant Not to Sue]

 

 
 

 

RELEASEE: TAURIGA SCIENCES, INC.
     
  By:

/s/ Stella M. Sung

  Name: Stella Sung, Ph.D
  Title: CEO/President
     
  DOC GREEN’S ACQUISITION SUB, LLC
     
  By:

/s/ Stella M. Sung

  Name: Stella Sung, Ph.D
  Title:

President and CEO of Tauriga Sciences, Inc., sole member

 

 
 

 

 

STANDSTILL AGREEMENT

 

THIS STANDSTILL AGREEMENT (this “ Agreement ”) is made as of July 15, 2014, by and among Honeywood, LLC, a California limited liability company (“ Honeywood ”), Daniel Kosmal, Elie Green and Ramona Rubin, (each, an “ Executive ”) and other Persons who from time to time become parties to the Merger Agreement (together with Honeywood and Executive, “ Members ”) and Tauriga Sciences, Inc., a Florida corporation (“ Tauriga ”). Tauriga, Honeywood, Executive, and, upon their execution hereof, the other Members party hereto are each referred to herein as a “ Party ” or collectively as the “ Parties ”.

 

RECITALS

 

WHEREAS , the Parties are parties to that certain Agreement and Plan of Merger, dated as of as of March 10, 2014, as amended (the “ Merger Agreement ”).

 

WHEREAS , pursuant to Section 4.2(m) of the Merger Agreement, the Members are required to deliver to Tauriga this Agreement as a condition to the consummation of the transactions set forth in the Merger Agreement.

 

WHEREAS , capitalized terms used herein without definition shall have the respective meanings ascribed thereto in the Merger Agreement.

 

NOW, THEREFORE , in consideration of the premises and the mutual promises herein made, and in consideration of the representations, warranties, and covenants herein contained, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound hereby, the Parties agree as follows.

 

AGREEMENT

 

1. The Standstill Obligation . During the Standstill Period (as defined below), without the prior written consent of Tauriga, each of the Members agrees that it shall not, nor shall any Member permit any of its affiliates (as such term is defined in the Exchange Act) to, nor shall any Member agree, or advise, assist, encourage, provide information or provide financing to others, or permit its affiliates to agree, or to advise, assist, encourage, provide information or provide financing to others, to, individually or collectively, directly or indirectly:

 

(a) acquire or offer to acquire or agree to acquire from any Person, directly or indirectly, by purchase or merger, through the acquisition of control of another Person, by joining a “group” (within the meaning of Section 13(d)(3) of the Exchange Act) or otherwise, beneficial ownership of any equity securities of Tauriga or any of its Subsidiaries, or direct or indirect rights (including securities convertible into or exchangeable or exercisable for any such equity securities) or options, warrants or other rights to acquire such beneficial ownership (or otherwise act in concert with respect to any such securities, rights, options, warrants or other rights with any Person that so acquires, offers to acquire or agrees to acquire); provided, however , that no such acquisition, offer to acquire or agreement to acquire shall be deemed to occur solely due to: (i) a stock split, reverse stock split, reclassification, reorganization or other transaction by Tauriga affecting any class of the outstanding capital stock of Tauriga generally that has been approved by a majority of the Continuing Directors of Tauriga or (ii) a stock dividend or other pro rata distribution by Tauriga to holders of its outstanding capital stock that has been approved by a majority of the Continuing Directors of Tauriga.

 

 
 

 

(b) except as expressly permitted by the proviso to paragraph (a) above, effect or seek, offer or propose (whether publicly or otherwise) to effect, or cause or participate in or in any way assist any other person to effect or seek, offer or propose (whether publicly or otherwise) to effect or participate in, (i) any acquisition of any debt or equity securities (or beneficial ownership thereof) or assets of Tauriga or any of its Subsidiaries; (ii) any tender or exchange offer or merger or other business combination involving Tauriga or any of its Subsidiaries; (iii) any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to Tauriga or any of its Subsidiaries;

 

(c) make, or in any way participate in, directly or indirectly, any “solicitation” of “proxies” to vote (as such terms are used in the Regulation 14A promulgated under the Exchange Act), or initiate, propose or otherwise solicit stockholders of Tauriga or its Subsidiaries for the approval of any stockholder proposals, in each case with respect to Tauriga or any of its Subsidiaries; provided, however , that the foregoing shall not apply to any Person who is a director of Tauriga acting in his capacity as a director of Tauriga with respect to matters approved by a majority of the Continuing Directors of Tauriga;

 

(d) form, join, in any way participate in, or encourage the formation of, a group (within the meaning of Section 13(d)(3) of the Exchange Act) with respect to any voting securities of Tauriga or any of its Subsidiaries;

 

(e) deposit any securities of Tauriga or any of its Subsidiaries into a voting trust, or subject any securities of Tauriga or any of its Subsidiaries to any Contract with respect to the voting of such securities, or other Contract having similar effect;

 

(f) alone or in concert with others, seek, or encourage or support any effort, to influence or control the management, Board of Directors, business, policies, affairs or actions of Tauriga;

 

(g) take any action which, in Tauriga’s reasonable opinion, will require Tauriga under applicable securities laws to make a public announcement regarding any of the types of matters set forth in paragraph (a) or (b) above;

 

(h) enter into any discussions or arrangements with any other Person with respect to any of the foregoing; or

 

(i) request Tauriga or any of its Subsidiaries (or any directors, officers, employees or agents of Tauriga or any of its Subsidiaries), directly or indirectly, to amend, waive or modify any provision of this Section 1 .

 

 
 

 

For purposes of this Agreement, “ Continuing Director ” means, with respect to any Person and any period, any individuals (A) who were members of the board of directors or other equivalent governing body of such entity immediately upon completion of the Merger, (B) whose election or nomination to that board or equivalent governing body was approved by the individuals referred to in clause (A) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body, or (C) whose election or nomination to that board or other equivalent governing body was approved by the individuals referred to in clauses (A) and (B) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body (excluding, in the case of both clause (B) and clause (C), any individual whose initial nomination for, or assumption of office as, a member of that board or equivalent governing body occurs as a result of an actual or threatened solicitation of proxies or consents for the election or removal of one or more directors by any Person or group other than a solicitation for the election of one or more directors by or on behalf of the board of directors or equivalent governing body).

 

2. The Standstill Period . Subject to Section 3 hereof, as used in this Agreement, the term “ Standstill Period ” shall mean the fifth (5 th ) anniversary of the Closing Date as defined in the Merger Agreement.

 

3. Transfer of Securities . Nothing contained in this Agreement shall limit or restrict the ability of any Member to sell, transfer, convey, deliver or grant an encumbrance upon (“ Transfer ”) the shares of Tauriga Common Stock, other than pursuant to applicable federal or state securities laws. This Agreement will not bind or restrict any non-affiliated Person to whom such shares of Tauriga Common Stock are transferred by a Member; provided, however , that no Member will Transfer such shares of Tauriga Common Stock to an affiliate (as defined in this Agreement), any member of the immediate family of such Member or estate planning vehicle for the benefit of any such Person (“ Affiliated Transferee ”) without requiring such Affiliated Transferee to enter into a joinder to this Agreement. Each such Affiliated Transferee shall, as a condition to such Transfer, enter into and execute any agreements, certificates or instruments reasonably required by Tauriga in order to give effect to the intents and purposes of this Agreement. Any Transfer to an Affiliated Transferee other than in accordance with this Section 3 shall be null and void and Tauriga and its transfer agent shall not be required to give effect to such Transfer on the books of Tauriga.

 

4. Specific Performance . Each of the Parties agrees that it is impossible to measure in money the damages which would accrue by reason of a Party’s failure to perform any of its obligations under this Agreement. It is agreed that the Parties hereto would be irreparably damaged in the event that this Agreement and would not have an adequate remedy at law were this Agreement not specifically performed. Accordingly, it is agreed that each of Tauriga and the other Members shall be entitled to an injunction to prevent breaches of this Agreement, and to specific performance of this Agreement and its terms and provisions. Such actions may be instituted in any competent court of the United States or any state or territory thereof having subject matter jurisdiction thereof. The Parties waive any requirement for the posting of a bond in respect of any action seeking injunctive relief or specific performance. A defaulting Party hereunder shall not argue, as a defense to any proceeding for specific performance or injunctive relief, that the Person seeking such relief has an adequate remedy at law.

 

5. Remedies Cumulative . The injunctive and equitable remedies set forth in Section 4 above, and the grant of an irrevocable proxy in this Agreement and all other remedies set forth in this Agreement and the Merger Agreement shall be in addition to any other rights or remedies which the parties may have at law or in equity. The rights and remedies herein provided are cumulative and none is exclusive of any other.

 

 
 

 

6. No Rule of Construction . The Parties acknowledge that each Party has been represented by counsel and all Parties have read and negotiated the language used in this Agreement. The Parties agree that, because all Parties participated in negotiating and drafting this Agreement, no rule of construction shall apply to this Agreement which construes ambiguous language in favor of or against any Party by reason of that Party’s role in drafting this Agreement.

 

7. Governing Law . This Agreement shall be construed and enforced in accordance with and governed by the laws of the State of Florida without regard to principles of conflicts of laws.

 

8. Notices . All notices, consents, directions, approvals, instructions, requests and other communications required or permitted by the terms of this Agreement shall be in writing, and shall be sent to the applicable Party at the following addresses or facsimile numbers, as applicable:

 

If to Tauriga:

 

Tauriga Sciences, Inc.

39 Old Ridgebury Road, Suite C4

Danbury, CT 06180

Attn: Seth M. Shaw

Telephone: (514) 840-3697

Fax: (514) 221-3336

 

With a copy to:

 

Nixon Peabody LLP

437 Madison Avenue
New York, New York 10014
Attn: Theodore J. Ghorra, Esq.

Telephone: (212) 940-3072

Fax: (855) 856-7298

 

If to any of the Members:

 

c/o Honeywood, LLC
1999 Harrison Street

Suite 1800

Oakland CA 94707

Attn: Daniel Kosmal

 

With a copy to:

 

Buchalter Nemer, PC

1000 Wilshire Boulevard

Suite 1500

Los Angeles, CA 90017

Attn: Jeremy Weitz, Esq. and Tanya Viner, Esq.

Tel: (213) 891-0700

Fax: (213) 630-5793

 

 
 

 

or to such other address or facsimile number as any Party may have furnished to each other Party in writing in accordance herewith. All notices, consents, directions, approvals, instructions, requests and other communications hereunder shall be sent and effective as follows: (i) on the business day delivered, when delivered personally, (ii) five (5) business days after mailing if mailed by registered or certified mail, return receipt requested (postage prepaid), (iii) on the next business day if sent by a nationally recognized overnight express courier service with all costs prepaid and provided evidence of delivery is available, or (iv) on the business day of a facsimile transmission if received on a business day before 5:00 p.m., local time, or on the next business day if received after that time, in each case provided that an automatic machine confirmation indicating the time of receipt is generated.

 

9. Amendments and Waivers . No breach of any covenant, agreement, warranty or representation shall be deemed waived unless expressly waived in writing by the Party who is entitled to assert such breach. No waiver of any right hereunder shall operate as a waiver of any other right or of the same or a similar right on another occasion. This Agreement may be modified only by a written instrument duly executed by the Parties hereto.

 

10. Entire Agreement . This Agreement contains the entire understanding of the Parties with respect to the subject matter hereof, and supersedes all prior representations, agreements and understandings relating to the subject matter hereof.

 

11. Severability . Any provision of this Agreement that is invalid, illegal or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability, without affecting in any way the remaining provisions hereof in such jurisdiction or rendering that or any other provision of this Agreement invalid, illegal or unenforceable in any other jurisdiction.

 

12. Counterparts; Signatures; Section Headings . This Agreement may be executed by the Parties in separate counterparts, each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute but one and the same instrument. A facsimile signature shall bind the signatory in the same way that an original signature would bind the signatory. The headings of each section, subsection or other subdivision of this Agreement are for reference only and shall not limit or control the meaning thereof.

 

[Remainder of page intentionally left blank]

 

 
 

 

IN WITNESS WHEREOF, this Agreement has been duly executed by the Parties hereto as of the date first written above.

 

  TAURIGA SCIENCES, INC.
     
  By: /s/ Stella M. Sung
  Name: Stella Sung. Ph.D
  Title:

CEO/Chairman

     
  HONEYWOOD, LLC
     
  By:

/s/ Daniel Kosmal

  Name: Daniel Kosmal
  Title:

President

     
    /s/ Daniel Kosmal
    Daniel Kosmal
     
    /s/ Elie Green
    Elie Green
     
    /s/ Ramona Rubin
    Ramona Rubin

 

[Signature page to Standstill and Voting Agreement]

 

 
 

 

 

 

Tauriga Sciences Inc. Completes Acquisition of Honeywood LLC, A California-Based Developer of Medicinal Cannabis Products, Including Doc Green’s Cream

 

LOS ANGELES, July 14, 2014 (GLOBE NEWSWIRE) -- Tauriga Sciences Inc. (OTCQB:TAUG) or (“Tauriga” or “the Company”), a diversified life sciences company, is pleased to announce that it has successfully completed its acquisition of California-based medicinal cannabis firm Honeywood LLC (“Honeywood”), the formulator for Doc Green’s topical cannabis cream and for other products. Under terms of the completed acquisition agreement, Honeywood will operate as a wholly owned subsidiary of Tauriga Sciences Inc., with all future revenues and profits (losses) to be reflected on Tauriga’s pro forma financial statements. The final acquisition terms result in stakeholders of Honeywood receiving 15.5% of Tauriga Sciences non-diluted shares of common stock outstanding immediately prior to closing. Honeywood’s principals have the opportunity to collectively earn up to an additional aggregate equal to 10% of Tauriga’s common stock outstanding (utilizing the same initial Closing Date) upon achieving the following gross revenue based milestones: upon the generation and receipt of $2.0MM of gross revenues derived strictly from the sale and licensing of Honeywood’s products, the three Honeywood principals shall each be issued either restricted stock or stock options equal to 1.6666% shares of Common Stock of Tauriga; upon the generation and receipt of an additional $2.0MM ($4.0 MM total gross revenues by Honeywood), its three principals shall each be issued an additional 1.6666% shares of Common Stock of Tauriga (each such additional issuance to be set off the outstanding shares immediately prior to the Closing Date).

 

Since its inception, Honeywood has been responsible for overseeing the product development of Doc Green’s Healing Collective, formulating and licensing its line of Doc Green’s Therapeutic Healing Cream, a cannabis infused shea butter lotion, that delivers the healing power of cannabis through the skin without psychoactive side effects. Doc Green’s itself is a California not for profit entity operating under California laws, regulations, and guidelines applicable to the State’s medicinal cannabis industry. Doc Green’s lotion was the first professionally packaged and widely distributed cannabis product on the California market, and has won much acclaim including a first (“1st”) prize award at the 2013 High Times Cannabis Cup (“Cannabis Cup”) for Best Non-Edible Medically Infused Product.

 

Honeywood is a key component in Tauriga’s natural wellness business. Honeywood is currently focused on increasing its capacity to produce and develop products, and is actively pursuing expansion opportunities in California as well as in other states where medical marijuana is legal. By completing the merger with Tauriga, Honeywood is confident that the quality of the management team and the access to working capital will enable both the acceleration of organic growth and expansion to new markets, resulting in new and greater revenues.

 

Tauriga’s Chairman & CEO, Dr. Stella M. Sung states, “The completion of this acquisition is a major milestone for Tauriga Sciences and its shareholders. Management looks forward to working with the Honeywood principals to develop and commercialize high quality products in the medicinal cannabis sector. The Doc Green’s topical cannabis cream is a compelling initial product for Tauriga’s natural wellness business. Many people who use the cream report effective and rapid relief from musculoskeletal pain, and they report that the cream does not produce any psychoactive effect.”

 

Honeywood LLC President Mr. Daniel Kosmal expressed, “The past 5 years have yielded amazing results in our ability to provide safe and natural cannabis healing products to the California market. We believe we have found the ideal partner with whom to achieve our vision of spreading the healing potential of the cannabis plant. With our combined leadership and resources, we look forward to rapidly expanding our product line and extending our reach.”

 

 
 

 

In addition to the Doc Green’s topical cannabis cream, which is already available in dispensaries in California, Honeywood has developed Vapura, a medicinal cannabis vapor cartridge that attaches to an e-cigarette battery and produces an effective and flavorful cannabis vapor. We anticipate that Vapura will be available for patients in compliance with California Health & Safety Code 11362.5 beginning in the third quarter of 2014.

 

Tauriga’s natural wellness business also includes “Cannabis Complements,” a line of non-cannabis containing dietary supplements which is being launched this summer. These dietary supplements will target cannabis-related effects, such as anxiety, memory and cognitive function, and appetite control. The supplements do not contain cannabis and can be sold nationwide to establish and build the Tauriga brand, especially in the 23 states where medicinal marijuana is legal.

 

The Global 100 law firm Nixon Peabody LLP has advised and represented Tauriga Sciences, Inc. with respect to this above-mentioned transaction.

 

About Tauriga Sciences, Inc.:

 

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On July 10, 2014, Tauriga acquired a California based topical cannabis cream company. Please visit the Company’s corporate website at www.tauriga.com .

 

NON SOLICITATION:

 

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

 

DISCLAIMER:

 

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

 

CONTACT: Tauriga Sciences, Inc.:
  Dr. Stella M. Sung,
  Chairman and Chief Executive Officer
  Tauriga Sciences, Inc.
  www.tauriga.com
  San Diego: + 1-858-353-5749
  Montreal: + 1-514-840-3697
  Email: ssung@tauriga.com